| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.03B | -27.9% |
| Gross profit | ¥0.01B | — |
| Operating income | ¥-0.00B | — |
| Net income | ¥-0.00B | — |
| Gross margin | 42.0% | Net margin -17.4% |
| Revenue Q/Q | -68.9% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.02B | 58.0% |
| R&D | ¥0.00B | 8.4% |
| SG&A | ¥0.01B | 45.8% |
| Tax & other | ¥-0.00B | -0.1% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
维尔利 ・ 潜能恒信 ・ 科德教育 ・ 佳士科技 ・ 福安药业 ・ 长荣股份 ・ 长海股份 ・ 节能铁汉 ・ *ST纳川 ・ 翰宇药业 ・ 高盟新材 ・ 海伦哲
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies